Malignant neoplasm of other specified male genital organs
ICD-10 C63.7 is a billable code used to indicate a diagnosis of malignant neoplasm of other specified male genital organs.
C63.7 refers to malignant neoplasms that arise in male genital organs not specifically classified elsewhere. This includes cancers of the penis, scrotum, and other specified areas such as the seminal vesicles and prostate. The clinical presentation may vary widely, with symptoms including abnormal growths, pain, and changes in urinary or sexual function. Diagnosis typically involves imaging studies, biopsies, and histopathological examination. Staging of the cancer is crucial for determining treatment options and prognosis, often utilizing the TNM classification system, which assesses tumor size, lymph node involvement, and metastasis. Additionally, PSA (Prostate-Specific Antigen) levels are significant in diagnosing and monitoring prostate cancer, with elevated levels indicating potential malignancy. Fertility considerations are also paramount, as treatments such as surgery or radiation can impact reproductive capabilities. Therefore, pre-treatment counseling regarding fertility preservation is essential for patients of reproductive age.
Detailed descriptions of tumor location, size, and staging; results of PSA tests; and any imaging studies performed.
Diagnosis and management of penile cancer, scrotal tumors, or seminal vesicle malignancies.
Urologists must ensure comprehensive documentation to support the complexity of the case and the chosen treatment plan.
Complete cancer staging information, treatment plans, and follow-up care details.
Management of advanced male genital cancers requiring chemotherapy or radiation therapy.
Oncologists should document the multidisciplinary approach to treatment, including referrals to fertility specialists if applicable.
Used in cases of prostate cancer management.
Document indication for surgery, preoperative assessments, and postoperative care.
Urologists should ensure that the procedure is linked to the diagnosis of malignancy.
Common symptoms include abnormal growths, pain, changes in urinary function, and sexual dysfunction. Patients may also present with lymphadenopathy or systemic symptoms if metastasis occurs.
